<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02832947</url>
  </required_header>
  <id_info>
    <org_study_id>025/15_2</org_study_id>
    <nct_id>NCT02832947</nct_id>
  </id_info>
  <brief_title>PK of Rivaroxaban in Bariatric Patients - Extension</brief_title>
  <official_title>Pharmacokinetics and Pharmacodynamics of Single Doses of Rivaroxaban in Obesity Patients Before and After Bariatric Surgery - The Extension Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Lausanne Hospitals</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Inselspital, Berne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim of this clinical Trial is the assessment of rivaroxaban PK/PD parameters in patients 6-8
      months after bariatric surgery
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Weight loss after bariatric surgery can putatively alter drug disposition of rivaroxaban.
      This may be due to an altered intestinal adaptations several months after the surgical
      procedure. The aim of this clinical trial is to investigate pharmacokinetic and
      pharmacodynamic parameters after single application of 10 mg rivaroxaban in patients with
      prior bariatric intervention (Roux-en-y-gastric bypass or sleeve gastrectomy 6-8 months ago).
      PK/PD parameters will be assessed during 12 hours after application of rivaroxaban.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC of rivaroxaban</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of rivaroxaban</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of rivaroxaban</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Prothrombin time (PT)</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Activated partial thromboplastin time (aPTT)</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Levels of Prothrombin fragment (F1+F2)</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Levels of Thrombin-antithrombin-complexes (TAT)</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Levels of D-Dimers</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Prophylaxis of Venous Thromboembolism</condition>
  <arm_group>
    <arm_group_label>Rivaroxaban Arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban 10 mg</intervention_name>
    <description>At study month 7 (+/-1 month), patients receive at 8 a.m. a single dose of 10 mg rivaroxaban. Study specific blood tubes are sampled the same day at the indicated time points from T -1h to T 12h.</description>
    <arm_group_label>Rivaroxaban Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with past elective bariatric surgery (Roux-en-Y gastric bypass surgery or
             sleeve gastrectomy 6-8 months ago)

          -  Patient aged 18 years and older

          -  BMI ≥ 35 kg/m2

          -  Women of child-bearing age: Willingness of using a double barrier contraception method
             during the study

          -  Written, informed consent

        Exclusion Criteria:

          -  Intake of oral anticoagulants (phenprocoumon, acenocoumarol, dabigatran, etexilate,
             apixaban etc.) 4 weeks prior to inclusion in the study

          -  Application of parenteral anticoagulants (unfractionated heparin, low molecular weight
             heparins, heparin derivates (fondaparinux etc.) 4 weeks prior to inclusion in the
             study

          -  Pharmacologic platelet inhibition 4 weeks prior to inclusion in the study

          -  Known coagulation disorders (e.g. Willebrand's disease, haemophilia)

          -  Evidence for deep vein thrombosis or pulmonary embolism in the personal history or in
             the history of first degree relatives

          -  Medical condition that is associated with an increased risk for VTE, i.e. active
             cancer disease, lupus erythematodes chronic inflammatory bowel disease

          -  Active, clinically significant bleeding

          -  Congenital or acquired bleeding disorder

          -  Uncontrolled severe hypertension

          -  Active gastrointestinal disease that can potentially lead to bleeding disorder:
             oesophagitis, gastritis, gastroesophageal reflux disease, chronic inflammatory bowel
             disease

          -  Vascular retinopathy

          -  Bronchiectasis or history of pulmonary bleeding

          -  Prior stroke or TIA

          -  Hereditary galactose intolerance, Lapp lactase deficiency, glucose-lactose
             malabsorption

          -  Severe renal impairment with a creatinine clearance (GFR) of &lt; 30ml/min

          -  Positive pregnancy test, pregnancy or nursing women

          -  High risk of bleeding (e.g. active ulcerative gastrointestinal disease)

          -  Known intolerance of the study medication rivaroxaban

          -  Concomitant treatment with strong CYP3A4 inhibitors (e.g. ketoconazole, itraconazole,
             lopinavir, ritonavir, indinavir)

          -  Concomitant treatment with an P-glycoprotein inhibitor and weak or moderate CYP3A4
             inhibitor (e.g. erythromycin, azithromycin, diltiazem, verapamil, quinidine,
             ranolazine, dronedarone, amiodarone, felodipine)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dino Kröll, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Inselspital, Berne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital, Inselspital Berne</name>
      <address>
        <city>Berne</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2016</study_first_submitted>
  <study_first_submitted_qc>July 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2016</study_first_posted>
  <last_update_submitted>April 10, 2017</last_update_submitted>
  <last_update_submitted_qc>April 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

